KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to -$259.3 million.

  • Royalty Pharma's Free Cash Flow rose 47.19% to -$259.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $944.7 million, marking a year-over-year increase of 544.72%. This contributed to the annual value of $263.3 million for FY2024, which is 69.82% down from last year.
  • Latest data reveals that Royalty Pharma reported Free Cash Flow of -$259.3 million as of Q3 2025, which was down 171.45% from $362.9 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Free Cash Flow high stood at $595.0 million for Q1 2025, and its period low was -$866.3 million during Q3 2021.
  • For the 3-year period, Royalty Pharma's Free Cash Flow averaged around $166.7 million, with its median value being $246.1 million (2024).
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 2,467.27% in 2021, then tumbled by 501.15% in 2024.
  • Royalty Pharma's Free Cash Flow (Quarterly) stood at $318.2 million in 2021, then climbed by 0.46% to $319.7 million in 2022, then slumped by 171.82% to -$229.6 million in 2023, then skyrocketed by 207.18% to $246.1 million in 2024, then surged by 47.19% to -$259.3 million in 2025.
  • Its Free Cash Flow stands at -$259.3 million for Q3 2025, versus $362.9 million for Q2 2025 and $595.0 million for Q1 2025.